There are 791 papers on heart failure with preserved ejection fraction in aging research: 70 trials and 316 observational studies in people, 80 in animals, 1 in cells, 312 reviews. The newest story, Nov 17, 2026: “Fine-particle pollution linked to heart failure types in China”.
Cardiometabolic stress induces heart failure with preserved ejection fraction in mice (two-hit protocol).
“Unlike young female mice, aged mice developed HFpEF, coinciding with impaired cardiac mitochondrial function and disrupted mitochondrial proteostasis.”
Alcohol was not clearly linked with heart failure with preserved ejection fraction in humans (Heavy drinkers compared with never drinkers) (HR 1.05, 95% CI 0.96–1.13).
“heavy drinking was significantly associated with HFrEF (HR: 1.13, 95% CI: 1.02, 1.24), not HFpEF (HR: 1.05, 95% CI: 0.96, 1.13).”
HumansHeavy drinkers compared with never drinkers>4 drinks/day and/or diagnosed with alcohol use disorderMean follow-up of 6.4 years91% mensn = 401,348
Heart failure with preserved ejection fraction impairs proteostasis in 3-hit HFpEF model.
“mitochondrial chaperones and proteases for protein quality control were reduced, leading to increased accumulation of ubiquitinated mitochondrial proteins and impaired mitochondrial proteostasis.”
Clinical journal of the American Society of Nephrology : CJASN·
Peak descending aortic circumferential strain
↓downin humans1
1 study
Heart failure with preserved ejection fraction is linked with lower peak descending aortic circumferential strain in humans (heart failure with preserved ejection fraction) (3.8% ± 1.6% vs 11.4% ± 2.2%, P < 0.02).
“Peak descending aortic strain (young: 11.4% ± 2.2%; older: 4.8% ± 1.6%; HFpEF 3.8% ± 1.6%) and absolute distension were lower (all, P < 0.02) in the older and HFpEF groups compared to the young.”
Humansheart failure with preserved ejection fraction
weight loss decreases heart failure with preserved ejection fraction in humans.
“Although robust trial evidence supports weight loss as a disease-modifying strategy in some conditions, including but not limited to type 2 diabetes and heart failure with preserved ejection fraction”
Carotid-femoral pulse wave velocity was not clearly linked with heart failure with preserved ejection fraction in humans after adjustment for potential confounders (HR 1.06 (95% CI 0.72-1.56)).
“cf-PWV velocity was also not associated with risk of HFpEF and HFrEF after adjustment for potential confounders”
Humansafter adjustment for potential confoundersn = 2,290
Cellular senescence raises the risk of heart failure with preserved ejection fraction.
“Cellular senescence and the ensuing senescence-associated secretory phenotype (SASP) significantly contribute to the pathogenesis and progression of HFpEF.”
Heart failure with preserved ejection fraction is associated with obesity in humans (suspected HFpEF in primary care).
“Patients with HFpEF were more likely to be obese, pre-frail or frail, report more dyspnoea and fatigue, were more functionally impaired, and less active than patients in whom HFpEF was refuted.”
Obesity is associated with heart failure with preserved ejection fraction.
“Obesity in women is linked to hyperinsulinemia, hyperandrogenism, chronic inflammation, impaired ovulation, infertility, visceral and epicardial adiposity, and obesity-related HFpEF.”
Heart failure with preserved ejection fraction is linked with a higher risk of mortality in humans (at 48 months, compared to non-HFpEF patients (4.6% all-cause, 1.5% cardiovascular)) (all-cause mortality 12.3% vs 4.6%, cardiovascular mortality 5.9% vs 1.5%, P < 0.05).
“At 48 months, cumulative all-cause mortality was 18.9%, 12.3%, and 4.6%, respectively, and cardiovascular mortality was 10.8%, 5.9%, and 1.5% (log-rank P < 0.05).”
Heart failure with preserved ejection fraction is linked with a higher risk of mortality in humans (HFpEF patients vs age- and gender-matched general population) (SMR 3.37, 95% CI: 2.4-4.7).
“HFpEF patients < 80 years had a three times higher mortality risk (SMR 3.37, 95% CI: 2.4-4.7)”
HumansHFpEF patients vs age- and gender-matched general population
Heart failure with preserved ejection fraction is associated with mortality in heart failure patients (HR 1.32, CI 1.08-1.61).
“Heart failure with preserved ejection fraction (HFpEF) was associated with a 32% (HR 1.32, CI 1.08-1.61, P = 0.007) higher mortality compared to HFrEF.”
Metabolic dysfunction-associated steatotic liver disease is associated with heart failure with preserved ejection fraction in humans.
“Shared risk factors and inflammatory pathways have highlighted a strong bidirectional association between MASLD and cardiovascular diseases, particularly HFpEF.”
Heart failure with preserved ejection fraction is associated with frailty in humans (heart failure) (55.2% vs. 46.8%, P = 0.043).
“The proportions of patients with physical frailty were 55.2% in HFpEF patients and 46.8% in HFrEF patients, and the proportion was significantly higher in HFpEF patients (P = 0.043).”
Heart failure with preserved ejection fraction is associated with frailty in humans (suspected HFpEF in primary care).
“Patients with HFpEF were more likely to be obese, pre-frail or frail, report more dyspnoea and fatigue, were more functionally impaired, and less active than patients in whom HFpEF was refuted.”
Ultra-processed foods are associated with heart failure with preserved ejection fraction in humans (without cardiovascular disease at baseline) (HR 1.096, 95% CI 1.016–1.183; upper 80% versus lowest 20%: HR 2.234, 95% CI 1.289–3.874).
“UPF intake remained significantly associated with HFpEF (HR 1.096; 95% CI 1.016–1.183), but not HFrEF.”
Ultra-processed foods are associated with heart failure with preserved ejection fraction in humans (phenotype-stratified analysis) (HR 1.11; 95% CI 1.02-1.19).
“When stratified by phenotype, UPF intake remained significantly associated with HFpEF (HR 1.11; 95% CI 1.02-1.19), but not HFrEF/HFmrEF.”
Clonal hematopoiesis of indeterminate potential is associated with heart failure with preserved ejection fraction in humans (patients undergoing treatment for solid tumors).
“Patients with CHIP were more likely to have coronary artery disease (CAD) (p-value <0.001) and HFpEF (p-value 0.007)”
Humanspatients undergoing treatment for solid tumorsheartn = 236
Inflammation is associated with heart failure with preserved ejection fraction in humans.
“A comorbidity-driven systemic proinflammatory state, together with coronary microvascular endothelial inflammation, has emerged as a central paradigm in HFpEF pathogenesis.”
Inflammation is associated with heart failure with preserved ejection fraction.
“inflammaging, a chronic, low-grade inflammatory state driven by immunosenescence, mitochondrial dysfunction, and cellular senescence, to progressive myocardial fibrosis, diastolic stiffness, and HFpEF development.”
Change in Kansas City Cardiomyopathy Questionnaire overall summary score
↑upin humans1
1 study
Heart failure with preserved ejection fraction is associated with change in Kansas City Cardiomyopathy Questionnaire overall summary score in humans (Compared with heart failure with reduced ejection fraction).
“the change over time differed significantly between HF types (p for time*HF type=0.005), with a greater improvement observed in HFpEF.”
Human trialCompared with heart failure with reduced ejection fraction1 yearn = 337
A prospective cohort followed 101,521 Chinese adults for a median 14.83 years, linking different pollution components to different heart failure subtypes.A prospective cohort followed 101,521 Chinese adults for a median 14.83 years, linking different pollution components to different heart failure subtypes.
Median survival was 14.6% lower in artery-disease-prone mice lacking the proteins in blood-vessel-lining cells than in comparison mice.Median survival was 14.6% lower in artery-disease-prone mice lacking the proteins in blood-vessel-lining cells than in comparison mice.